John W Beck
CIK 1292404 · Chief Financial Officer · last filed 2021-07-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RDEA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1880 CENTURY PARK EAST, SUITE 1000
LOS ANGELES, CA 90067
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARTELO BIOSCIENCES, INC. (ARTLW) Delisted | Director | — | $0.01 | — | $0 | 3 | 2021-07-26 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Chief Financial Officer | — | — | — | $0 | 3 | 2020-05-19 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | SVP, Finance & Operations, CFO | 0 | — | — | -$1.41M | 13 | 2012-06-20 |
| MBRX | Chief Financial Officer | 5 | $7.74 | $39 | -$235.4K | 9 | 2008-04-03 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| MBRX | Direct | 5 | 100.0% | 2007-06-21 |
| Joseph Beck 2002 Irrevocable Trust See Footnote |
0 | 0.0% | 2007-06-05 | |
| Total | 5 | |||
| No longer reported | ||||
| See Footnote (2) | 0 | — | last 2007-03-09 | |
Recent Filings · Page 2 of 3
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-02-16 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Mixed | — | -$155.7K | EDGAR |
| 2010-12-16 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-05-17 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Mixed | — | -$128.5K | EDGAR |
| 2009-12-18 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-08-17 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Mixed | — | -$35.8K | EDGAR |
| 2009-05-21 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Mixed | — | -$45.6K | EDGAR |
| 2008-12-19 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-07-07 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-04-03 | MBRX | Grant (A) | — | $0 | EDGAR |
| 2008-01-04 | Ardea Biosciences, Inc./DE (RDEA) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).